Articles from Praxis Precision Medicines, Inc.

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on March 3, 2025, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 2,000 shares of its common stock and restricted stock unit awards covering an aggregate of 7,288 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 4, 2025

BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in five upcoming investor conferences:
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 4, 2025

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided an update on the interim analysis for Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET), an update on other therapies in development and a financial update.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · February 28, 2025

BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on February 3, 2025, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 4,050 shares of its common stock and restricted stock unit awards covering an aggregate of 3,038 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · February 4, 2025

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences:
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · February 3, 2025

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · January 12, 2025

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA at the Westin St. Francis Hotel on Wednesday, January 15, 2025 at 2:15pm PST.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · January 6, 2025

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · December 18, 2024

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · December 3, 2024

BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the American Epilepsy Society (AES) Annual Meeting, being held from December 6 to 10, 2024 in Los Angeles, California.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 26, 2024

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 6, 2024

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 6, 2024

BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 1, 2024

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the presentation of a poster and platform talk showcasing its Phase 3 clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the Movement Disorders Society (MDS) 2024 International Congress taking place in Philadelphia, Pennsylvania, September 27 – October 1, 2024.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · September 26, 2024

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be attending and presenting at two upcoming conferences:
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · September 5, 2024

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), being held from September 7 to 11, 2024 in Rome, Italy.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · September 4, 2024

Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · September 3, 2024

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · September 2, 2024

Up to four programs in registrational phase by 2025
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · August 13, 2024

BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the second quarter ended June 30, 2024, before the financial markets open on Tuesday, August 13, 2024.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · August 5, 2024

BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 3, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 300 shares of its common stock and restricted stock unit awards covering an aggregate of 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employee’s entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · June 4, 2024

BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · May 17, 2024

Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · May 13, 2024

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024, before the U.S. financial markets open.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · May 10, 2024

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,800 shares of its common stock and restricted stock unit awards covering an aggregate of 5,851 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · May 3, 2024

Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · April 12, 2024

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will take part in upcoming conferences in April.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · April 5, 2024

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on April 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase 300 shares of its common stock and restricted stock unit awards covering 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employee’s entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · April 2, 2024

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares and pre-funded warrants in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 530,973 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 2, 2024, subject to market conditions and the satisfaction of customary closing conditions.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 28, 2024

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or prefunded warrants in lieu thereof) sold in the offering at the public offering price, less the underwriting discount and commission.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 27, 2024

In the 45 mg cohort, 100% of patients achieved a complete response
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 26, 2024

Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 25, 2024

Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be completed in 1H 2024 with topline results in 2H 2024
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 5, 2024

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the TD Cowen 44th Annual Health Care Conference, taking place in Boston from March 4 – 6, 2024. In addition to conducting one-on-one investor meetings, management will participate in a corporate panel discussion.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 1, 2024

BOSTON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on February 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 1,600 shares of its common stock and restricted stock unit awards covering an aggregate of 1,450 shares of its common stock to two new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · February 2, 2024

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,168,275 shares of its common stock at a public offering price per share of $35.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 1,056,725 shares of common stock at a purchase price of $35.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares and pre-funded warrants in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 633,750 additional shares of common stock at the public offering price, less the underwriting discount and commission. The offering is expected to close on or about January 16, 2024, subject to market conditions and the satisfaction of customary closing conditions.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · January 11, 2024

BOSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or prefunded warrants in lieu thereof) sold in the offering at the public offering price, less the underwriting discount and commission.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · January 10, 2024

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg cohort
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · January 8, 2024

Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · January 5, 2024

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 28, 2023

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 21, 2023

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental and epileptic encephalopathy (DEE). The EMA’s PRIME designation provides enhanced development support for priority medicines that target an unmet need and was granted based on the Part 1 data from the EMBRAVE study that showed a reduction in seizures and improvement in seizure free days, as well as preclinical data.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 16, 2023

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 7, 2023

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a panel discussion titled “CNS Companies Looking To Address High Unmet High Prevalence and High Value Diseases” at the Truist Securities BioPharma Symposium on November 8, 2023.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 2, 2023

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · October 2, 2023

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will host a R&D Day on Monday, October 2, at 9:00 a.m. EDT, virtually and in person in New York City.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · September 27, 2023

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 12 p.m. EDT.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · September 7, 2023

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will present data from two of its clinical-stage epilepsy programs at the upcoming 35th International Epilepsy Congress (IEC), to be held on September 2-6, 2023 in Dublin, Ireland.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · August 31, 2023

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society’s (MDS) International Congress of Parkinson's Disease and Movement Disorders®, taking place in Copenhagen, Denmark.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · August 28, 2023

On track to initiate Phase 3 studies for ulixacaltamide in Q4 2023 after favorable End-of-Phase 2 meeting with FDA
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · August 9, 2023

Patients dosed with ulixacaltamide up to 14 weeks showed maintained or improved efficacy results, as measured by mean changes in the modified Activities of Daily Living 11 (mADL111)
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · August 8, 2023

Composite qEEG measure showed change from placebo after first dose of 5 mg
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · August 7, 2023

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate at the 2023 Wedbush PacGrow Healthcare Conference on Wednesday, August 9, 2023 at 9:30a.m. ET on the panel David vs. Goliath - How Can Orphan Epilepsy Development Accelerate and Broaden its Reach? Please contact your Wedbush representative for details about how to participate.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · August 3, 2023

Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · June 22, 2023

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 55,150,000 shares of its common stock at a public offering price per share of $0.95 and, in lieu of shares of common stock, a pre-funded warrant to purchase up to an aggregate of 7,050,000 shares of common stock at a purchase price of $0.9499, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds from the offering are expected to be approximately $59.1 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares and the pre-funded warrant in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 9,299,690 additional shares of common stock at the public offering price, less the underwriting discount and commission. The offering is expected to close on or about June 21, 2023, subject to market conditions and the satisfaction of customary closing conditions.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · June 15, 2023

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock. All shares in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering at the public offering price, less the underwriting discount and commission.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · June 15, 2023

Phase 3 program to include one parallel group study and one randomized withdrawal study
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · June 9, 2023

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will present at the 2023 Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:00 a.m. ET.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · June 2, 2023

Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · May 11, 2023

PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider than current market leader based on MES model
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · May 11, 2023

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its clinical stage programs at the upcoming American Academy of Neurology (AAN) 2023 Annual Meeting, held April 22-27, 2023 in Boston, Massachusetts.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · April 19, 2023

Ulixacaltamide essential tremor end-of-phase 2 meeting with FDA scheduled for June 2023
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · April 17, 2023

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will present at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 12:45 p.m. ET.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · April 6, 2023

BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 3, 2023

Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · March 3, 2023

Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · February 7, 2023

BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · December 13, 2022

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the American Epilepsy Society (AES) 2022 Annual Meeting, held December 2-6, 2022 in Nashville, Tennessee.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 28, 2022

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced plans to initiate the PRAX-562 Phase 2 EMBOLD study for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEEs), following U.S. Food and Drug Administration (FDA) authorization to proceed with the study as proposed by Praxis, up to the planned maximum dose of 1.0 mg/kg/day. The EMBOLD Study is expected to initiate in the U.S in the first quarter of 2023, with two distinct cohorts in early-onset SCN2A-DEE and SCN8A-DEE patients. Topline results for both cohorts are expected in the second half of 2023.
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 28, 2022

PRAX-944 Phase 2b Essential1 study topline results for essential tremor expected in 1Q23
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 9, 2022

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQPRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
By Praxis Precision Medicines, Inc. · Via GlobeNewswire · November 7, 2022